drugset / Trial / NCT03679845

Study to Assess Sarilumab in Halting Progression of Morphea

NCT03679845

NaSingle-groupOpen-labelTreatment

Summary

An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.

Timeline

Start
2019-09-01
Primary completion
2021-06-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody 200 mg

Indications